Literature DB >> 16687403

The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter.

Tokameh Mahmoudi1, Maribel Parra, Robert G J Vries, Steven E Kauder, C Peter Verrijzer, Melanie Ott, Eric Verdin.   

Abstract

Tat is a critical viral transactivator essential for human immunodeficiency virus (HIV) gene expression. Activation involves binding to an RNA stem-loop structure and recruitment of the positive transcription elongation factor b. Tat also induces the remodeling of a single nucleosome in the HIV promoter. However, the mechanism of this remodeling has remained unclear. Knockdown of INI-1 and BRG-1, two components of the SWI/SNF chromatin-remodeling complex, suppressed Tat-mediated transactivation. Cells lacking INI-1 (G401 and MON) or BRG-1 (C33A) exhibited defective transactivation by Tat that was restored upon INI-1 and BRG-1 expression, respectively. Tat was co-immunoprecipitated with several SWI/SNF subunits, including INI-1, BRG-1, and beta-actin. The SWI/SNF complex interacted with the integrated HIV promoter in a Tat-dependent manner. We also found that INI-1 and BRG-1 synergized with the p300 acetyltransferase to activate the HIV promoter. This synergism depended on the acetyltransferase activity of p300 and on Tat Lys(50) and Lys(51). In conclusion, Tat-mediated activation of the HIV promoter requires the SWI/SNF complex in synergy with the coactivator p300.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687403     DOI: 10.1074/jbc.M603336200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  98 in total

1.  The viral protein Tat can inhibit the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Björn D Kuhl; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  Mutual information analysis reveals coevolving residues in Tat that compensate for two distinct functions in HIV-1 gene expression.

Authors:  Siddharth S Dey; Yuhua Xue; Marcin P Joachimiak; Gregory D Friedland; John C Burnett; Qiang Zhou; Adam P Arkin; David V Schaffer
Journal:  J Biol Chem       Date:  2012-01-17       Impact factor: 5.157

3.  Characterization of HIV Tat modifications using novel methyl-lysine-specific antibodies.

Authors:  Sara Pagans; Naoki Sakane; Martina Schnölzer; Melanie Ott
Journal:  Methods       Date:  2010-07-06       Impact factor: 3.608

4.  Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells.

Authors:  Hao Yin; Yuhao Zhang; Xin Zhou; Huanzhang Zhu
Journal:  Mol Biol Rep       Date:  2010-12-23       Impact factor: 2.316

Review 5.  Functional roles of HIV-1 Tat protein in the nucleus.

Authors:  Yana R Musinova; Eugene V Sheval; Carla Dib; Diego Germini; Yegor S Vassetzky
Journal:  Cell Mol Life Sci       Date:  2015-10-27       Impact factor: 9.261

6.  Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency.

Authors:  Young Kyeung Kim; Cyril F Bourgeois; Richard Pearson; Mudit Tyagi; Michelle J West; Julian Wong; Shwu-Yuan Wu; Cheng-Ming Chiang; Jonathan Karn
Journal:  EMBO J       Date:  2006-07-27       Impact factor: 11.598

7.  CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency.

Authors:  Mudit Tyagi; Jonathan Karn
Journal:  EMBO J       Date:  2007-11-15       Impact factor: 11.598

Review 8.  Integration site selection by retroviral vectors: molecular mechanism and clinical consequences.

Authors:  René Daniel; Johanna A Smith
Journal:  Hum Gene Ther       Date:  2008-06       Impact factor: 5.695

9.  Tat controls transcriptional persistence of unintegrated HIV genome in primary human macrophages.

Authors:  Beatrix Meltzer; Deemah Dabbagh; Jia Guo; Fatah Kashanchi; Mudit Tyagi; Yuntao Wu
Journal:  Virology       Date:  2018-03-15       Impact factor: 3.616

10.  15-Deoxy-Delta12,14-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification.

Authors:  Parisa Kalantari; Vivek Narayan; Andrew J Henderson; K Sandeep Prabhu
Journal:  FASEB J       Date:  2009-03-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.